Australia - inglese - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: povidone; colloidal anhydrous silica; magnesium stearate - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Stati Uniti - inglese - NLM (National Library of Medicine)

validus pharmaceuticals llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - hiprex is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of hiprex and other antibacterial drugs, hiprex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. hiprex (methenamine hippurate tablets usp) is contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should not be given to patients taking sulfonamides becau

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - methenamine hippurate - oral tablet - 1gram

Canada - inglese - Health Canada

axxess pharma inc. - methenamine; sodium bicarbonate; tartaric acid - powder (effervescent) - 0.5g; 4.6g; 3.8g - methenamine 0.5g; sodium bicarbonate 4.6g; tartaric acid 3.8g - urinary anti-infectives

Canada - inglese - Health Canada

produits francais labs inc. - methenamine mandelate; methylene blue - tablet - 250mg; 10mg - methenamine mandelate 250mg; methylene blue 10mg - urinary anti-infectives

Canada - inglese - Health Canada

graceway pharmaceuticals - methenamine hippurate - tablet - 1g - methenamine hippurate 1g - urinary anti-infectives

Stati Uniti - inglese - NLM (National Library of Medicine)

apace packaging, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - uroav-b capsules are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uroav-b capsules are contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

Stati Uniti - inglese - NLM (National Library of Medicine)

apace packaging, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) -  uroav-81 tablets is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uroav-81 tablets is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

Stati Uniti - inglese - NLM (National Library of Medicine)

key therapeutics - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), benzoic acid (unii: 8skn0b0mim) (benzoic acid - unii:8skn0b0mim), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), hyoscyamine (unii: px44xo846x) (hyoscyamine - unii:px44xo846x) - u r i s e d™ is indicated for the relief of discomfort of the lower urinary tract caused by hypermotility resulting from inflammation or diagnostic procedures and in the treatment of cystitis, urethritis, and trigonitis when caused by organisms which maintain or produce an acid urine and are susceptible to formaldehyde. glaucoma, urinary bladder neck obstruction, pyloric or duodenal obstruction, or cardiospasm. hypersensitivity to any of the ingredients. a dependence on the use of u r i s e d™ has not been reported and due to the nature of its ingredients, abuse of u r i s e d™ is not expected.